Author:
Crippa Luciano,Falanga Anna,Finazzi Guido,Marongiu Francesco,Palareti Gualtiero,Poli Daniela,Testa Sophie,Tiraferri Eros,Tosetto Alberto,Tripodi Armando,Manotti Cesare,Pengo Vittorio
Abstract
SummaryDabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF). They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with.
Reference42 articles.
1. Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2. Boehringer Ingelheim. Boehringer Ingelheim's Pradaxa available in US pharmacies starting Wednesday, November 3 [press release]. November 1, 2010. Available at: http://www.prnewswire.com/news-releases/boehringer-ingelheims-pradaxa-available-in-us-pharmacies-starting-wednesday-november-3-106474818.html.
3. Results of Rivaroxaban on AF: Presentation to AHA - November 15, 2010 Chicago - (ROCKET AF t trial).
4. Connolly SJ, Eikelboom J, Joyner C, et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.
5. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
Cited by
151 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献